[免疫介导的血液系统疾病的诊断与治疗进展。主题：四、近期主题；2. 利妥昔单抗治疗免疫性血小板减少症和血栓性血小板减少性紫癜] - Suppr | 超能文献

[Recent progress of diagnosis and treatment for immune-mediated hematological diseases. Topics: IV. Recent topics; 2. Rituximab for ITP and TTP].

作者信息

Miyakawa Yoshitaka

出版信息

Nihon Naika Gakkai Zasshi. 2014 Jul 10;103(7):1654-9. doi: 10.2169/naika.103.1654.

DOI:10.2169/naika.103.1654

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Recent progress of diagnosis and treatment for immune-mediated hematological diseases. Topics: IV. Recent topics; 2. Rituximab for ITP and TTP].[免疫介导的血液系统疾病的诊断与治疗进展。主题：四、近期主题；2. 利妥昔单抗治疗免疫性血小板减少症和血栓性血小板减少性紫癜]

Nihon Naika Gakkai Zasshi. 2014 Jul 10;103(7):1654-9. doi: 10.2169/naika.103.1654.

2

Rituximab therapy for refractory thrombotic thrombocytopenic purpura and autoimmune-mediated thrombocytopenia in systemic lupus erythematosus.利妥昔单抗治疗难治性血栓性血小板减少性紫癜及系统性红斑狼疮中自身免疫介导的血小板减少症

South Med J. 2008 Sep;101(9):943-4. doi: 10.1097/SMJ.0b013e3181809ebd.

3

[Rituximab for treatment of immune thrombocytopenia and thrombotic thrombocytopenic purpura].利妥昔单抗治疗免疫性血小板减少症和血栓性血小板减少性紫癜

Rinsho Ketsueki. 2019;60(5):480-487. doi: 10.11406/rinketsu.60.480.

4

Concurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in a patient with metastatic neuroendocrine tumour successfully treated with rituximab-CVP.一名转移性神经内分泌肿瘤患者同时患有血栓性血小板减少性紫癜和免疫性血小板减少性紫癜，使用利妥昔单抗 - CVP方案成功治疗。

BMJ Case Rep. 2010 Nov 12;2010:bcr0720103144. doi: 10.1136/bcr.07.2010.3144.

5

ITP and TTP: interpreting evidence in light of patient values.特发性血小板减少性紫癜和血栓性血小板减少性紫癜：根据患者价值观解读证据。

Blood. 2015 Mar 5;125(10):1514-5. doi: 10.1182/blood-2015-01-622555.

6

Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature.一名已知患有特发性（免疫性）血小板减少性紫癜的患者发生产后血栓性血小板减少性紫癜：病例报告及文献综述

J Med Case Rep. 2018 Jun 1;12(1):147. doi: 10.1186/s13256-018-1692-1.

7

Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.利妥昔单抗治疗难治性特发性血小板减少性紫癜（ITP）和血栓性血小板减少性紫癜（TTP）：三例报告

Am J Hematol. 2005 Jan;78(1):49-54. doi: 10.1002/ajh.20243.

8

[Rituximab for managing refractory thrombotic thrombocytopenic purpura: a report of three cases].

Rinsho Ketsueki. 2013 Feb;54(2):205-9.

9

[Exciting investigator-initiated clinical trials].[令人兴奋的研究者发起的临床试验]

Rinsho Ketsueki. 2016;57(10):2145-2150. doi: 10.11406/rinketsu.57.2145.

10

Successful treatment of refractory immune thrombocytopenia with rituximab in a 10-week-old infant.利妥昔单抗成功治疗一名10周龄婴儿的难治性免疫性血小板减少症。

J Pediatr Hematol Oncol. 2013 May;35(4):e174-7. doi: 10.1097/MPH.0b013e31828308be.

引用本文的文献

1

TMA secondary to SLE: rituximab improves overall but not renal survival.继发于系统性红斑狼疮的血栓性微血管病：利妥昔单抗改善整体而非肾脏存活率。

Clin Rheumatol. 2018 Jan;37(1):213-218. doi: 10.1007/s10067-017-3793-4. Epub 2017 Aug 30.